NAGIOS: RODERIC FUNCIONANDO

Proteinuria-lowering effects of proprotein convertase subtilisin/kexin type 9 inhibitors in chronic kidney disease patients : a real-world multicentric study

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Proteinuria-lowering effects of proprotein convertase subtilisin/kexin type 9 inhibitors in chronic kidney disease patients : a real-world multicentric study

dc.contributor.author	Muñoz Ramos, Patricia
dc.contributor.author	Gil Giraldo, Yohana
dc.contributor.author	Álvarez Chiva, Vicente
dc.contributor.author	Arroyo, David
dc.contributor.author	Sango Merino, Cristina
dc.contributor.author	Moncho, Francesc
dc.contributor.author	Ocaña, Javier
dc.contributor.author	Reque, Javier
dc.contributor.author	Sánchez Álvarez, Emilio
dc.contributor.author	Górriz Teruel, Jose Luis
dc.contributor.author	Quiroga, Borja
dc.date.accessioned	2022-06-16T13:36:27Z
dc.date.available	2022-06-16T13:36:27Z
dc.date.issued	2021
dc.identifier.citation	Muñoz Ramos, Patricia Gil Giraldo, Yohana Álvarez Chiva, Vicente Arroyo, David Sango Merino, Cristina Moncho, Francesc Ocaña, Javier Reque, Javier Sánchez Álvarez, Emilio Górriz Teruel, Jose Luis Quiroga, Borja 2021 Proteinuria-lowering effects of proprotein convertase subtilisin/kexin type 9 inhibitors in chronic kidney disease patients : a real-world multicentric study Metabolites
dc.identifier.uri	https://hdl.handle.net/10550/83191
dc.description.abstract	Control of dyslipidemia in chronic kidney disease (CKD) is not always guaranteed with statins and/or ezetimibe. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have opened up a new era in lipid control, but their effect on renal function and proteinuria in real life have not yet been evaluated. The aim of the present study was to analyze the evolution of renal function and proteinuria in a cohort of CKD patients treated with PCSK9i. This retrospective multicentric cohort study included CKD patients treated with PCSK9i. Baseline epidemiological data, comorbidities and laboratory findings (including estimated glomerular filtration rate [eGFR], proteinuria and lipid profile) were collected. The evolution of renal function, proteinuria and lipid profile was analyzed during the 1-year follow-up. The cohort included 76 patients (68% male, mean age 66 ± 10 years). The mean baseline creatinine was 1.55 ± 0.77 mg/dL, and the mean eGFR was 52 ± 22 mL/min/1.73 m2. Reductions in LDL-cholesterol, total cholesterol and triglycerides during the first month were 51 ± 25%, 32 ± 25% and 11 ± 40%, respectively, levels that remained stable throughout the first year (p < 0.001 for LDL-cholesterol and total cholesterol trends and p = 0.002 for triglyceride trend). During follow-up, proteinuria improved from 57 (9-481) to 30 (7-520) mg/g (p = 0.021). In addition, eGFR remained stable, and no adverse events were reported. In our cohort, dyslipidemia treatment with PCSK9i was associated with decreased proteinuria in CKD patients, an effect that might be due to reduced lipid nephrotoxicity. Clinical trials are needed to further investigate whether this impact on proteinuria can significantly slow CKD progression in the long term.
dc.language.iso	eng
dc.relation.ispartof	Metabolites, 2021
dc.subject	Insuficiència renal crònica
dc.title	Proteinuria-lowering effects of proprotein convertase subtilisin/kexin type 9 inhibitors in chronic kidney disease patients : a real-world multicentric study
dc.type	journal article	es_ES
dc.date.updated	2022-06-16T13:36:27Z
dc.identifier.doi	10.3390/metabo11110760
dc.identifier.idgrec	154218
dc.rights.accessRights	open access	es_ES